Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06907043 · ClinicalTrials.gov registry record · Phase 1
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
A Phase 1 study of Advanced Solid Tumors, sponsored by Eikon Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 10
- Study locations
NCT06907043: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Eikon Therapeutics.
NCT06907043 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 130 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (34% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06907043, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Eikon Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2
Primary Outcome
A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). The number of participants who experience a DLT will be reported.
Conditions Studied
Interventions
- DRUG EIK1004-001 (IMP1707-001)
Study Locations (10)
Texas
- MD Anderson - Houston
- NEXT Oncology - San Antonio
Colorado
- Sarah Cannon Research Institute at HealthOne - Denver
Florida
- Florida Cancer Center - Lake Mary
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Virginia
- NEXT Virginia - Fairfax
Victoria
- PASO Medical - Frankston
Chongqing Municipality
- Chongqing University Cancer Hospital - Chongqing
Shandong
- Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital) - Jinan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT06907043 shows while recruiting
NCT06907043 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which EIK1004-001 (IMP1707-001) is the first listed.
NCT06907043 lists 10 locations in 9 states (Texas, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT06907043 about?
NCT06907043 is a clinical study titled "A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.". This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutati...
What is the current status of trial NCT06907043?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2025-04-30. Estimated completion is 2028-12.
What conditions does trial NCT06907043 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06907043?
The interventions under investigation include: EIK1004-001 (IMP1707-001) (DRUG).
Who is sponsoring clinical trial NCT06907043?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06907043 being conducted?
This trial has 10 study locations across Colorado, Florida, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06907043's enrollment target sits among peer trials
130 65th of 144 higher than 80 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI